Characteristics of CLL patients according to CD38 expression
| . | All patients . | CD38− . | CD38 bimodal expression . | CD38+ . | P . |
|---|---|---|---|---|---|
| No. of cases (%) | 108 | 62 (57.4) | 30 (27.8) | 16 (14.8) | NA |
| Mean age, y | 70 | 68 | 73 | 70 | NA |
| Sex, M/F | 67/41 | 36/25 | 21/9 | 9/7 | NA |
| Mean duration of follow-up, mo | 90 | 90 | 88 | 95 | NA |
| Risk status | <.0011-153 | ||||
| Low risk*(%) | 78/108 (72.2) | 53/62 (85.5) | 18/30 (60.0) | 7/16 (43.8) | |
| Intermediate risk*(%) | 22/108 (20.4) | 8/62 (12.9) | 10/30 (33.3) | 4/16 (25.0) | |
| High risk*(%) | 8/108 (7.4) | 1/62 (1.6) | 2/30 (6.7) | 5/16 (31.3) | |
| Disease status | <.0011-153 | ||||
| Stable disease (%) | 69/108 (63.9) | 54/62 (87.1) | 11/30 (36.7) | 4/16 (25.0) | |
| Progressive disease (%) | 39/108 (36.1) | 8/62 (12.9) | 19/30 (63.3) | 12/16 (75.0) | |
| Mutation | <.0011-153 | ||||
| Somatically Ig mutated (%) | 49/82 (59.8) | 39/44 (88.6) | 8/25 (32.0) | 2/13 (15.4) | |
| Somatically Ig unmutated (%) | 33/82 (40.2) | 5/44 (11.4) | 17/25 (68.0) | 11/13 (84.6) | |
| Autoimmune manifestations (%) | 20/108 (18.5) | 6/20 (30) | 9/20 (45) | 5/20 (25) | .0291-153 |
| Treatment | <.0011-153 | ||||
| Not requiring treatment (%) | 61/108 (56.5) | 46/62 (74.2) | 11/30 (36.7) | 4/16 (25.0) | |
| Requiring treatment (%) | 47/108 (43.5) | 16/62 (25.8) | 19/30 (63.3) | 12/16 (75.0) | |
| Blood parameters | |||||
| Mean β2-microglobulin count, mg/L† | 2.85 | 2.1 | 3.9 | 4.1 | <.0011-155 |
| Mean Hb count, g/dL | 12.9 | 13.6 | 12.1 | 11.5 | <.0011-155 |
| Mean platelet count, per μL | 167 000 | 188 500 | 140 100 | 134 500 | .0021-155 |
| Mean lymphocyte count, per μL | 36 400 | 25 700 | 46 300 | 58 900 | .0051-155 |
| Mean LDT, %‡ | 94.6 | 33.0 | 123.0 | 282.0 | .0031-155 |
| . | All patients . | CD38− . | CD38 bimodal expression . | CD38+ . | P . |
|---|---|---|---|---|---|
| No. of cases (%) | 108 | 62 (57.4) | 30 (27.8) | 16 (14.8) | NA |
| Mean age, y | 70 | 68 | 73 | 70 | NA |
| Sex, M/F | 67/41 | 36/25 | 21/9 | 9/7 | NA |
| Mean duration of follow-up, mo | 90 | 90 | 88 | 95 | NA |
| Risk status | <.0011-153 | ||||
| Low risk*(%) | 78/108 (72.2) | 53/62 (85.5) | 18/30 (60.0) | 7/16 (43.8) | |
| Intermediate risk*(%) | 22/108 (20.4) | 8/62 (12.9) | 10/30 (33.3) | 4/16 (25.0) | |
| High risk*(%) | 8/108 (7.4) | 1/62 (1.6) | 2/30 (6.7) | 5/16 (31.3) | |
| Disease status | <.0011-153 | ||||
| Stable disease (%) | 69/108 (63.9) | 54/62 (87.1) | 11/30 (36.7) | 4/16 (25.0) | |
| Progressive disease (%) | 39/108 (36.1) | 8/62 (12.9) | 19/30 (63.3) | 12/16 (75.0) | |
| Mutation | <.0011-153 | ||||
| Somatically Ig mutated (%) | 49/82 (59.8) | 39/44 (88.6) | 8/25 (32.0) | 2/13 (15.4) | |
| Somatically Ig unmutated (%) | 33/82 (40.2) | 5/44 (11.4) | 17/25 (68.0) | 11/13 (84.6) | |
| Autoimmune manifestations (%) | 20/108 (18.5) | 6/20 (30) | 9/20 (45) | 5/20 (25) | .0291-153 |
| Treatment | <.0011-153 | ||||
| Not requiring treatment (%) | 61/108 (56.5) | 46/62 (74.2) | 11/30 (36.7) | 4/16 (25.0) | |
| Requiring treatment (%) | 47/108 (43.5) | 16/62 (25.8) | 19/30 (63.3) | 12/16 (75.0) | |
| Blood parameters | |||||
| Mean β2-microglobulin count, mg/L† | 2.85 | 2.1 | 3.9 | 4.1 | <.0011-155 |
| Mean Hb count, g/dL | 12.9 | 13.6 | 12.1 | 11.5 | <.0011-155 |
| Mean platelet count, per μL | 167 000 | 188 500 | 140 100 | 134 500 | .0021-155 |
| Mean lymphocyte count, per μL | 36 400 | 25 700 | 46 300 | 58 900 | .0051-155 |
| Mean LDT, %‡ | 94.6 | 33.0 | 123.0 | 282.0 | .0031-155 |